Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress. At the ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

An expert discusses how comparing the durability and treatment effects of newer minimally invasive therapies to gold standard transurethral resection of the prostate (TURP) or holmium laser ...

Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management. Panelists discuss how IsoPSA’s predictive ...

Incorporating mpMRI before TURBT improves bladder cancer-specific survival in patients with suspected MIBC. The BladderPath trial aimed to reduce time to radical treatment by comparing mpMRI before ...

Chan shares how her passion for research and desire to impact patients on a broader scale led her from academia to industry. In this episode of Pearls & Perspectives, host Amy Pearlman, MD, welcomes ...

Adjuvant durvalumab plus tremelimumab improved DFS in resected RCC, especially in high-risk patients, with a 43% reduction in recurrence risk. The trial enrolled patients into three arms, with the ...